경북바이오산단개발

비상장계속사업자

Kyeongbuk Bio Industrial Complex Development Co., Ltd

이세면

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

경북바이오산단개발

Business Reg. No. 7498800516 · CEO 이세면

I.Investment Overview

Target경북바이오산단개발 (7498800516)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명경북바이오산단개발
영문명Kyeongbuk Bio Industrial Complex Development Co., Ltd
대표자이세면
사업자등록번호7498800516
법인등록번호1711110035030
설립일2016.11.14

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW5.82020126.6202165.52022146.72023350.82024
영업이익100M KRW-2.8202010.120214.8202214.72023742024
순이익100M KRW-162020-2.12021-142022-6.2202364.52024
Item20242023202220212020
자산총계9.9억원275.9억원351.2억원402억원292.9억원
부채총계13.8억원344.2억원413.4억원450.2억원339억원
자본총계-3.9억원-68.4억원-62.2억원-48.2억원-46.1억원
매출액350.8억원146.7억원65.5억원126.6억원5.8억원
영업이익74억원14.7억원4.8억원10.1억원-2.8억원
순이익64.5억원-6.2억원-14억원-2.1억원-16억원

VI.Financial Ratios

FY2024 basis

21.09%

영업이익률

18.39%

순이익률

649.35%

ROA

ROE

부채비율

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

경북바이오산단개발 투심보고서 | Alpha Lenz